Dual Antiplatelet Therapy Duration Following Percutaneous Coronary Intervention: Time for a Change.
作者信息
Kereiakes Dean J
机构信息
The Christ Hospital Heart and Vascular Institute, Cincinnati, Ohio.
Lindner Center for Research and Education, Cincinnati, Ohio.
出版信息
J Soc Cardiovasc Angiogr Interv. 2025 Feb 18;4(2):102510. doi: 10.1016/j.jscai.2024.102510. eCollection 2025 Feb.
Abstract
摘要
相似文献
1
Dual Antiplatelet Therapy Duration Following Percutaneous Coronary Intervention: Time for a Change.经皮冠状动脉介入治疗后的双联抗血小板治疗持续时间：是时候做出改变了。
J Soc Cardiovasc Angiogr Interv. 2025 Feb 18;4(2):102510. doi: 10.1016/j.jscai.2024.102510. eCollection 2025 Feb.
2
Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.接受冠状动脉介入治疗后接受双联抗血小板治疗和三联治疗的患者的出血风险：ADAPTT 回顾性基于人群的队列研究。
Health Technol Assess. 2023 May;27(8):1-257. doi: 10.3310/MNJY9014.
3
Efficacy and Safety Outcomes of Short Duration Antiplatelet Therapy with Early Cessation of Aspirin Post Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.短期抗血小板治疗并早期停用阿司匹林在经皮冠状动脉介入治疗后的疗效和安全性结局：系统评价和荟萃分析。
Curr Cardiol Rev. 2021;17(6):e051121190712. doi: 10.2174/1573403X17666210126104053.
4
Shortened Duration of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Contemporary Clinical Review.经皮冠状动脉介入治疗后双联抗血小板治疗疗程的缩短：一项当代临床综述
Interv Cardiol. 2023 Dec 11;18:e31. doi: 10.15420/icr.2023.19. eCollection 2023.
5
Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.替格瑞洛单用或替格瑞洛加阿司匹林用于急性冠脉综合征患者经皮冠状动脉介入治疗后 1 至 12 个月（ULTIMATE-DAPT）：一项随机、安慰剂对照、双盲临床试验。
Lancet. 2024 May 11;403(10439):1866-1878. doi: 10.1016/S0140-6736(24)00473-2. Epub 2024 Apr 7.
6
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention.糖尿病患者经皮冠状动脉介入治疗后1个月双联抗血小板治疗后的氯吡格雷单药治疗
JACC Cardiovasc Interv. 2023 Jan 9;16(1):19-31. doi: 10.1016/j.jcin.2022.09.053. Epub 2022 Dec 14.
7
In-Hospital Outcomes of Dual Loading Antiplatelet Therapy in Patients 75 Years and Older With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Findings From the CCC-ACS (Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome) Project.75 岁及以上急性冠状动脉综合征行经皮冠状动脉介入治疗患者双联抗血小板治疗的住院结局：来自 CCC-ACS（改善中国心血管疾病治疗-急性冠状动脉综合征）项目的研究结果。
J Am Heart Assoc. 2018 Mar 30;7(7):e008100. doi: 10.1161/JAHA.117.008100.
8
State of the art: Oral antiplatelet therapy.最新技术水平：口服抗血小板治疗
JRSM Cardiovasc Dis. 2016 Jun 1;5:2048004016652514. doi: 10.1177/2048004016652514. eCollection 2016 Jan-Dec.
9
Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All-Cause Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention.经皮冠状动脉介入治疗后限时双重抗血小板治疗临床试验中出血、主要不良心血管事件和全因死亡率的汇总分析。
J Am Heart Assoc. 2020 Aug 18;9(16):e017109. doi: 10.1161/JAHA.120.017109. Epub 2020 Aug 11.
10
Tailoring antiplatelet therapy in older patients with coronary artery disease.为老年冠心病患者定制抗血小板治疗方案。
Platelets. 2023 Dec;34(1):2285446. doi: 10.1080/09537104.2023.2285446. Epub 2023 Dec 5.
本文引用的文献
1
Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks.根据临床、缺血和出血风险评估经皮冠状动脉介入治疗后抗血小板单药治疗的比较。
J Am Coll Cardiol. 2023 Oct 17;82(16):1565-1578. doi: 10.1016/j.jacc.2023.07.031.
2
Short-Term DAPT and DAPT De-Escalation Strategies for Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis.短期 DAPT 与急性冠状动脉综合征患者的 DAPT 降级策略：系统评价和网络荟萃分析。
Circ Cardiovasc Interv. 2023 Sep;16(9):e013242. doi: 10.1161/CIRCINTERVENTIONS.123.013242. Epub 2023 Aug 23.
3
Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions.替格瑞洛单药治疗冠脉介入术后出血及缺血风险。
J Am Coll Cardiol. 2023 Aug 22;82(8):687-700. doi: 10.1016/j.jacc.2023.05.062.
4
P2Y Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events.P2Y 抑制剂或阿司匹林单药治疗用于冠心病事件的二级预防。
J Am Coll Cardiol. 2023 Jul 11;82(2):89-105. doi: 10.1016/j.jacc.2023.04.051.
5
P2Y Inhibitor or Aspirin Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Network Meta-Analysis.经皮冠状动脉介入治疗后双联抗血小板治疗后应用 P2Y 抑制剂或阿司匹林：网状荟萃分析。
JACC Cardiovasc Interv. 2022 Nov 28;15(22):2239-2249. doi: 10.1016/j.jcin.2022.08.009. Epub 2022 Oct 26.
6
Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study.经皮冠状动脉介入治疗后阿司匹林与氯吡格雷用于长期维持单药治疗：HOST-EXAM扩展研究
Circulation. 2023 Jan 10;147(2):108-117. doi: 10.1161/CIRCULATIONAHA.122.062770. Epub 2022 Nov 7.
7
Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.急性冠状动脉综合征患者双联抗血小板治疗 1 至 2 个月后氯吡格雷单药治疗与 12 个月双联抗血小板治疗的比较：STOPDAPT-2 ACS 随机临床试验。
JAMA Cardiol. 2022 Apr 1;7(4):407-417. doi: 10.1001/jamacardio.2021.5244.
8
Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes.急性冠状动脉综合征经皮冠状动脉介入治疗后短期 DAPT 与降级治疗
JACC Cardiovasc Interv. 2022 Feb 14;15(3):268-277. doi: 10.1016/j.jcin.2021.11.028.
9
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2021 ACC/AHA/SCAI 冠状动脉血运重建指南：美国心脏病学会/美国心脏协会联合临床实践指南委员会的报告。
J Am Coll Cardiol. 2022 Jan 18;79(2):e21-e129. doi: 10.1016/j.jacc.2021.09.006. Epub 2021 Dec 9.
10
Risk-Benefit of 1-Year DAPT After DES Implantation in Patients Stratified by Bleeding and Ischemic Risk.根据出血和缺血风险分层的患者接受药物洗脱支架植入术后1年双联抗血小板治疗的风险效益
J Am Coll Cardiol. 2021 Nov 16;78(20):1968-1986. doi: 10.1016/j.jacc.2021.08.070.
Zotero 插件